News

Basel, Switzerland. June 30, 2021, 9am CEST BioVersys adds experienced personnel to key management positions. BioVersys AG is further strengthening its management team with the appointments of Dr. Stephan Amrein as Head of CMC and Dr. Isabelle Andrieux-Meyer as Medical Director. Stephan joins BioVersys with 17 years of experience in pharmaceutical product development.  Most recently, […]

Basel, Switzerland. June 1, 2021, 9am CET CARB-X funds BioVersys up to US$ 15.34 million to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics, targeting difficult to treat ESKAPE pathogens BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with

Basel, Switzerland. May 18, 2021, 9am CET BioVersys is strengthening its executive management team with the appointment of Martin Bott as Chief Financial Officer as of May 17, 2021. Martin will lead financial operations at BioVersys and support the company in its continued evolution as one of the leading, clinical stage biotech companies developing novel

Basel, Switzerland. April 14, 2021. 09:00 CEST European Investment Bank and BioVersys sign a financing agreement of up to €20 million to facilitate the development of new treatments against life-threatening resistant bacterial infections. The venture debt loan is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the European Union’s research

Basel, Switzerland. Februar 25, 2021. 09:00 CEST BioVersys and consortium partners TASK Foundation and GSK have been awarded 2.7 million Euro from European and Developing Countries Trial Partnership (EDCTP) for the further development of BVL-GSK098 with ethionamide in a Phase 2a tuberculosis clinical trial study. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focusing

Basel, Switzerland. January 12, 2021. 09:00 CEST BioVersys is proud to announce together with its partner GSK the first dosing of our Tuberculosis asset BVL-GSK098 in clinical Phase I. This is a great achievement for this groundbreaking program. For the first time, a small molecule targeting bacterial transcriptional regulators, is clinically assessed. We would like

Basel, Switzerland. November 18, 2021. 09:00 CEST BioVersys has reached a major milestone by entering clinical development with the start of Phase 1 testing of BV100 in healthy volunteers. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focused on developing small molecules for multidrug-resistant bacterial infections with applications in AntiMicrobial Resistance (AMR) and targeted

Basel, Switzerland. September 1, 2020. 09:00 CEST BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candidates into first in human clinical trials and has also strengthened its board with the appointment of Dr. Eduard Holdener. BioVersys AG, a privately owned,

Basel, Switzerland, July 14th, 2020. 09:00 CEST BioVersys and partners, the Institut Pasteur de Lille and the University of Lille, from Région Hauts-de-France, sign a long-term collaboration agreement creating a unique cross-border cluster of research excellence focused on unmet medical needs in antimicrobial resistance. BioVersys continues to strengthen ties with two institutes of scientific excellence,

BVL-GSK098 IS BEING DEVELOPED FOR THE TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS INFECTIONS Basel, Switzerland. June, 23 rd , 2020. 09:00 CEST BioVersys develops BVL-GSK098, in collaboration with GSK, as an entirely new mechanism to potentiate and overcome resistance of ethionamide in tuberculosis. BioVersys AG a privately owned, multi-asset Swiss pharmaceutical company focusing on research and